CLAIM #50307 · PM (PM) · 2025Q2 earnings call · Jul 22, 2025 · due Dec 31, 2025
“As we progress our commercial pilot in Austin, we also launched a second pilot in Fort Lauderdale during the quarter with further initiative planned in the coming months as we prepare for the at scale launch of IQOS Iluma once authorized by the FDA.”
Emmanuel Babeau · CFO
In context
“H2. We continue to target plus 10% to plus 12% HTU adjusted IMS growth for the year. Continuous IQOS innovation on devices and consumables combined with investments in brand equity are fundamental pillars of our growth. The rollout of the Illuma Eye technology now present in over 30 markets, remains ongoing. We are expanding the portfolio of Livia tobacco free consumable, with promising initial results from recently launched new test variants and flavor capsules. We also commenced the rollout of a resin pack design on our core premium terrier HTUs as well as the expansion of our mainstream price offering, Delia, with excellent results in markets such as Germany, and Poland. In the US, we continue with small scale IQOS three pilots which are generating considerable adult consumer interest. As we progress our commercial pilot in Austin, we also launched a second pilot in Fort Lauderdale during the quarter with further initiative planned in the coming months as we prepare for the at scale launch of IQOS Iluma once authorized by the FDA. Our second flagship premium smoke-free brand, Zeen, leads a category which has the potential to fundamentally reshape the consumption of nicotine for the substantial net benefit of global public health as adult smokers increasingly switch to smoke-free product. Q2 can shipments grew by plus 43% on a global basis and and offtake reaccelerated strongly in the u in the US which I'll come back to in more detail. Building on ZYN US strengths, our global rollout continued to advance with Q2 international can volume up plus 65% year on year or a remarkable plus 179% excluding the Nordics. The growth of our international business reflects both market expansion and strong offtake growth, supported by expanding production capacity in new geography. Notable strong performances include our global tra”
Verify independently
SEC filings for PM ↗ · Claim quote is verbatim from the 2025Q2 earnings call.